Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • CareersExpand
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / Therapeutics - Page 37

Therapeutics

University of British Columbia received $14 million in federal funding for COVID-19 research
Biotechnology | COVID-19 | Diagnostics | Therapeutics | Vaccine

University of British Columbia received $14 million in federal funding for COVID-19 research

On Jun. 25, 2020, researchers at the University of British Columbia announced they had received a combined total…

Read More University of British Columbia received $14 million in federal funding for COVID-19 researchContinue

SIGA Technologies announced deliveries of oral TPOXX to HHS valued at approximately $32 million
Biotechnology | Infectious Disease | Therapeutics

SIGA Technologies announced deliveries of oral TPOXX to HHS valued at approximately $32 million

On Jun. 25, 2020, SIGA Technologies announced the deliveries of oral TPOXX (tecovirimat) to the U.S. Department of…

Read More SIGA Technologies announced deliveries of oral TPOXX to HHS valued at approximately $32 millionContinue

Seattle researchers teamed up to build hi-res brain map of Alzheimer’s disease
Biotechnology | Diagnostics | Disease | Neurology | NIH | Therapeutics

Seattle researchers teamed up to build hi-res brain map of Alzheimer’s disease

On Jun. 25, 2020, the Allen Institute announced a new a new $40.5 million collaborative research center in…

Read More Seattle researchers teamed up to build hi-res brain map of Alzheimer’s diseaseContinue

RedHill Biopharma announced data from severe COVID-19 patients showed substantial benefit to patients
Biotechnology | COVID-19 | Therapeutics

RedHill Biopharma announced data from severe COVID-19 patients showed substantial benefit to patients

On Jun. 24, 2020, RedHill Biopharma announced that results from the treatment of the first severe COVID-19 patients…

Read More RedHill Biopharma announced data from severe COVID-19 patients showed substantial benefit to patientsContinue

Mateon selected by IBM Watson Health for use of IBM Clinical Development Solution to support clinical COVID-19 vaccine candidates
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Mateon selected by IBM Watson Health for use of IBM Clinical Development Solution to support clinical COVID-19 vaccine candidates

On Jun. 24, 2020, Oncotelic, a wholly owned subsidiary of Mateon Therapeutics, announced that IBM has granted access…

Read More Mateon selected by IBM Watson Health for use of IBM Clinical Development Solution to support clinical COVID-19 vaccine candidatesContinue

Mateon selected IQVIA for its randomized, controlled, multi-menter clinical study to test OT-101 as treatment for COVID-19 patients
Biotechnology | COVID-19 | Therapeutics

Mateon selected IQVIA for its randomized, controlled, multi-menter clinical study to test OT-101 as treatment for COVID-19 patients

On Jun. 23, 2020, Mateon Therapeutics announced it had selected IQVIA to manage C001, a Phase 2 randomized,…

Read More Mateon selected IQVIA for its randomized, controlled, multi-menter clinical study to test OT-101 as treatment for COVID-19 patientsContinue

Catalent partnered with ViralClear Pharmaceuticals on potential treatment for COVID-19
Biotechnology | COVID-19 | Life Science History | Pharmaceutical | Therapeutics

Catalent partnered with ViralClear Pharmaceuticals on potential treatment for COVID-19

On Jun. 22, 2020, Catalent announced that it had signed an agreement with ViralClear Pharmaceuticals, a subsidiary of…

Read More Catalent partnered with ViralClear Pharmaceuticals on potential treatment for COVID-19Continue

Taconic Biosciences announced distribution of critical COVID-19 mouse model
COVID-19 | Infectious Disease | Therapeutics | Vaccine

Taconic Biosciences announced distribution of critical COVID-19 mouse model

On Jun. 22, 2020, Taconic Biosciences announced an exclusive agreement with the University of Texas Medical Branch at…

Read More Taconic Biosciences announced distribution of critical COVID-19 mouse modelContinue

The NIH halted clinical trial of hydroxychloroquine
Biotechnology | COVID-19 | Infectious Disease | NIH | Therapeutics

The NIH halted clinical trial of hydroxychloroquine

On Jun. 20, 2020, the National Institutes of Health (NIH) announced that a clinical trial to evaluate the…

Read More The NIH halted clinical trial of hydroxychloroquineContinue

The FDA approved first therapy for rare disease that causes low phosphate blood levels, bone softening
Biotechnology | FDA | Therapeutics

The FDA approved first therapy for rare disease that causes low phosphate blood levels, bone softening

On Jun. 18, 2020, the U.S. Food and Drug Administration (FDA) approved Ultragenyx Pharmaceutical ‘s Crysvita (burosumab-twza) injection…

Read More The FDA approved first therapy for rare disease that causes low phosphate blood levels, bone softeningContinue

Tonix Pharma and Southern Research announced expansion of COVID-19 vaccine collaboration
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Tonix Pharma and Southern Research announced expansion of COVID-19 vaccine collaboration

On Jun. 18, 2020, Tonix Pharmaceuticals announced an expansion of its strategic collaboration with Southern Research to include…

Read More Tonix Pharma and Southern Research announced expansion of COVID-19 vaccine collaborationContinue

ViralClear opened enrollment with first patient dosing in phase II human trial of anti-viral MMPD oral solution for treatment of COVID-19
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

ViralClear opened enrollment with first patient dosing in phase II human trial of anti-viral MMPD oral solution for treatment of COVID-19

On Jun. 17, 2020, BioSig Technologies, and its subsidiary, ViralClear, announced that it had commenced patient enrollment with…

Read More ViralClear opened enrollment with first patient dosing in phase II human trial of anti-viral MMPD oral solution for treatment of COVID-19Continue

WHO announced preliminary results about dexamethasone use in treating critically ill COVID-19 patients
Biotechnology | COVID-19 | Therapeutics | WHO

WHO announced preliminary results about dexamethasone use in treating critically ill COVID-19 patients

On Jun. 16, 2020, the World Health Organization (WHO) announced that initial clinical trial results from the United…

Read More WHO announced preliminary results about dexamethasone use in treating critically ill COVID-19 patientsContinue

San Diego’s scientific and medical institutes collaborated on large-scale research program to study spread of COVID-19
Biotechnology | COVID-19 | Diagnostics | Non-Profit Research | Therapeutics

San Diego’s scientific and medical institutes collaborated on large-scale research program to study spread of COVID-19

On Jun. 16, 2020, a consortium that includes many of San Diego’s top medical and scientific research institutes…

Read More San Diego’s scientific and medical institutes collaborated on large-scale research program to study spread of COVID-19Continue

The FDA warned of newly discovered potential drug interaction that may reduce effectiveness of COVID-19 treatment
Biotechnology | COVID-19 | FDA | Infectious Disease | Therapeutics

The FDA warned of newly discovered potential drug interaction that may reduce effectiveness of COVID-19 treatment

On Jun. 15, 2020, the U.S. Food and Drug Administration (FDA) warned health care providers about a newly…

Read More The FDA warned of newly discovered potential drug interaction that may reduce effectiveness of COVID-19 treatmentContinue

The FDA revoked Emergency Use Authorization for chloroquine and hydroxychloroquine
Biotechnology | COVID-19 | FDA | Infectious Disease | Therapeutics

The FDA revoked Emergency Use Authorization for chloroquine and hydroxychloroquine

On Jun. 15, 2020, the U.S. Food and Drug Administration (FDA) revoked the emergency use authorization (EUA) that…

Read More The FDA revoked Emergency Use Authorization for chloroquine and hydroxychloroquineContinue

The FDA permitted marketing of first game-based digital therapeutic to improve attention function in children with ADHD
Biotechnology | Diagnostics | Disease | FDA | Medical Device | Neurology | Therapeutics

The FDA permitted marketing of first game-based digital therapeutic to improve attention function in children with ADHD

On Jun. 15, 2020, the U.S. Food and Drug Administration (FDA) permitted marketing of the first game-based digital…

Read More The FDA permitted marketing of first game-based digital therapeutic to improve attention function in children with ADHDContinue

Mayo Clinic Study of Humanigen’s lenzilumab showed rapid recovery and discharged in severe and critical COVID-19 patients
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

Mayo Clinic Study of Humanigen’s lenzilumab showed rapid recovery and discharged in severe and critical COVID-19 patients

On Jun. 15, 2020, Humanigen announced data on the first clinical use of lenzilumab in 12 COVID-19 patients….

Read More Mayo Clinic Study of Humanigen’s lenzilumab showed rapid recovery and discharged in severe and critical COVID-19 patientsContinue

SIGA Technologies announced Department of Defense increased funding to develop posteExposure prophylactic indication for TPOXX
Biotechnology | FDA | Therapeutics

SIGA Technologies announced Department of Defense increased funding to develop posteExposure prophylactic indication for TPOXX

On Jun. 15, 2020, SIGA Technologies announced the U.S. Department of Defense (DoD) increased research and development funding…

Read More SIGA Technologies announced Department of Defense increased funding to develop posteExposure prophylactic indication for TPOXXContinue

Dr. Reddy’s Laboratories entered into a licensing agreement with Gilead Sciences for Remdesivir
Biotechnology | COVID-19 | Therapeutics

Dr. Reddy’s Laboratories entered into a licensing agreement with Gilead Sciences for Remdesivir

On Jun. 13, 2020, Dr. Reddy’s Laboratories announced that it had entered into a non-exclusive Licensing Agreement with…

Read More Dr. Reddy’s Laboratories entered into a licensing agreement with Gilead Sciences for RemdesivirContinue

CIRM board approved two additional COVID-19 projects
Biotechnology | COVID-19 | Non-Profit Research | Therapeutics

CIRM board approved two additional COVID-19 projects

On Jun. 12, 2020, the California Institute for Regenerative Medicine (CIRM) awarded $349,999 to Dr. Vaithilingaraja Arumugaswami at…

Read More CIRM board approved two additional COVID-19 projectsContinue

The FDA approved drug to treat infants and children with HIV
Biotechnology | CDC | HIV | Therapeutics

The FDA approved drug to treat infants and children with HIV

On Jun. 12, 2020, the U.S. Food and Drug Administration (FDA) approved ViiV Healthcare’s Tivicay (dolutegravir) tablets and…

Read More The FDA approved drug to treat infants and children with HIVContinue

FDA approved Bristol-Myers’ Opdivo’ (nivolumab) for treatment of patients with advanced esophageal squamous cell carcinoma
Biotechnology | FDA | Medicine | Pharmaceutical | Therapeutics

FDA approved Bristol-Myers’ Opdivo’ (nivolumab) for treatment of patients with advanced esophageal squamous cell carcinoma

On Jun. 11, 2020, Bristol-Myers Squibb announced that Opdivo (nivolumab) was approved by the FDA for the treatment…

Read More FDA approved Bristol-Myers’ Opdivo’ (nivolumab) for treatment of patients with advanced esophageal squamous cell carcinomaContinue

Brain cells can harbor and spread HIV virus to the body
Biotechnology | HIV | Therapeutics

Brain cells can harbor and spread HIV virus to the body

On Jun. 11, 2020, researchers have found that astrocytes, a type of brain cell can harbor HIV and…

Read More Brain cells can harbor and spread HIV virus to the bodyContinue

BioCryst’s galidesivir stops Zika viral replication in primate model
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics

BioCryst’s galidesivir stops Zika viral replication in primate model

On Jun. 11, 2020, BioCryst Pharmaceuticals announced new data published in Science Translational Medicine that show, in a…

Read More BioCryst’s galidesivir stops Zika viral replication in primate modelContinue

Two science publications highlight potential of REGN-COV2 anti-viral antibody cocktail to protect against SARS-CoV-2 escape mutants
Biotechnology | COVID-19 | Therapeutics

Two science publications highlight potential of REGN-COV2 anti-viral antibody cocktail to protect against SARS-CoV-2 escape mutants

On Jun. 11, 2020, Regeneron announced that Science had accepted for publication two papers describing the creation of…

Read More Two science publications highlight potential of REGN-COV2 anti-viral antibody cocktail to protect against SARS-CoV-2 escape mutantsContinue

NIH funded study to evaluate drugs prescribed to children with COVID-19
COVID-19 | NIH | Therapeutics

NIH funded study to evaluate drugs prescribed to children with COVID-19

On Jun. 10, 2020, researchers funded by the National Institutes of Health (NIH) launched an effort to evaluate…

Read More NIH funded study to evaluate drugs prescribed to children with COVID-19Continue

COVID-19 mouse model announced to speed search for drugs, vaccines
Biotechnology | COVID-19 | Therapeutics

COVID-19 mouse model announced to speed search for drugs, vaccines

On Jun. 10, 2020, Washington University School of Medicine in St. Louis reported they had developed a mouse…

Read More COVID-19 mouse model announced to speed search for drugs, vaccinesContinue

OraSure received BARDA funding for Coronavirus Antibody ELISA using oral fluid samples
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics

OraSure received BARDA funding for Coronavirus Antibody ELISA using oral fluid samples

On Jun. 10, 2020, OraSure Technologies announced it had been awarded a $629,217 contract from the Biomedical Advanced…

Read More OraSure received BARDA funding for Coronavirus Antibody ELISA using oral fluid samplesContinue

RedHill Biopharma submited COVID-19 clinical trial application for phase 2/3 study with Opaganib in Russia
Biotechnology | COVID-19 | Therapeutics

RedHill Biopharma submited COVID-19 clinical trial application for phase 2/3 study with Opaganib in Russia

On Jun. 10, 2020, RedHill Biopharma announced it had submitted a Clinical Trial Application (CTA) with the Ministry…

Read More RedHill Biopharma submited COVID-19 clinical trial application for phase 2/3 study with Opaganib in RussiaContinue

Page navigation

Previous PagePrevious 1 … 35 36 37 38 39 … 106 Next PageNext
  • Categories
  • Timeline
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemical
  • Clinical Research
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1712
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Life Science Banner Advertising
  • Advertise Your Life Science Jobs

Legal

  • Privacy Policy
  • Terms of Use

© 2025 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • Careers
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search